Study protocol of a prospective, non-interventional cohort study evaluating the benefits of transjugular intrahepatic portosystemic shunt in patients with hepatocellular carcinoma receiving first-line atezolizumab plus bevacizumab (NISTIPS TRITICC-4, IKF092)
18 affiliations
- 1Clinic for Gastroenterology, Hepatology & Infectious Diseases, University Hospital of Düsseldorf, Düsseldorf, Germany
- 2Center for Integrated Oncology - Aachen Bonn Cologne Duesseldorf (CIO-ABCD), Duesseldorf, Germany
- 3Hospital Northwest, University Cancer Center Frankfurt, Frankfurt, Germany
- 4The Frankfurt Institute of Clinical Cancer Research IKF GmbH, Frankfurt am Main, Germany
- 5Department of Internal Medicine I, University Hospital of Bonn, Bonn, Germany
- 6Medical Department III, University Hospital of Aachen, Aachen, Germany
- 7Center for Integrated Oncology - Aachen Bonn Cologne Duesseldorf (CIO-ABCD), Aachen, Germany
- 8Department of Internal Medicine I, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany
- 9Department of Medicine II, University Hospital, LMU Munich, Munich, Germany
- 10Department of Gastroenterology, Hepatology and Endocrinology, University Hospital Frankfurt, Frankfurt, Germany
- 11Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, Rheumatology and Infectious Diseases University Hospital Regensburg, Regensburg, Germany
- 12Cancer Center Esslingen, Klinikum Esslingen, Germany
- 13Department of Internal Medicine B, University Hospital Münster, Münster, Germany
- 14Department of Gastroenterology and Hepatology, Essen University Hospital, Essen, Germany
- 15Department of Medicine IV, Gastroenterology, Hepatology and Infectious Diseases, Heidelberg University, Heidelberg, Germany
- 16German Cancer Research Center (DKFZ) Heidelberg, Experimental Hepatology, Inflammation and Cancer, Heidelberg, Germany
- 17Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité-University Medicine, Berlin, Germany
- 18TUM School of Medicine and Health, Department for Internal Medicine II, Technical University of Munich, TUM University Hospital, Munich, Germany
Abstract
Background: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality, with most patients diagnosed at an advanced stage. Atezolizumab plus bevacizumab is a current standard first-line therapy; however, outcomes are strongly influenced by underlying cirrhosis and clinically significant portal hypertension (CSPH). Complications such as ascites and variceal bleeding may limit treatment continuation, particularly as bevacizumab increases bleeding risk. Transjugular intrahepatic portosystemic shunt (TIPS) reduces portal pressure and may improve outcomes, but its role in patients receiving immunoncology-based systemic therapy remains unclear.
Methods: NISTIPS TRITICC-4 is a prospective, multicentre, non-interventional cohort study conducted at up to 25 centers in Germany. A total of 350 adult patients with cirrhosis and unresectable or metastatic HCC receiving first-line atezolizumab plus bevacizumab will be enrolled. Patients are allocated to two cohorts: TIPS in situ plus atezolizumab and bevacizumab or atezolizumab plus bevacizumab alone, according to routine clinical practice.
The primary endpoint is time to deterioration of liver function (TTDL), defined as persistent worsening of liver parameters for >4 weeks. Secondary endpoints include overall survival, time on treatment, overall response rate, time to new extrahepatic lesions or death, and safety with focus on bleeding and TIPS-related complications.
Time-to-event endpoints will be analyzed using Kaplan–Meier methods and Cox models. Propensity score matching will be applied to adjust for confounding. Analyses are exploratory.
Discussion: This study will provide real-world evidence on the impact of TIPS in HCC patients receiving atezolizumab plus bevacizumab and may support more individualized management strategies in this high-risk population.
Clinical trial registration: www.clinicaltrials.gov identifier is NCT07365930
Related
- Early Prognostic Value of the Freiburg Index of Post-Transjugular Intrahepatic Portosystemic Shunt Survival in Patients With Hepatocellular Carcinoma Undergoing Liver Transplantation
- Dual-pathway targeted therapy for decompensated cirrhosis: Combined transjugular intrahepatic portosystemic shunt and cyclooxygenase-2 inhibition
- Prognostic Value of Serial Alkaline Phosphatase-to-Albumin Ratio for Mortality After Transjugular Intrahepatic Portosystemic Shunt
- Reduction of transjugular intrahepatic portosystemic shunts using the 6-10 mm GORE VIATORR TIPS endoprosthesis with controlled expansion
- Clot Out, Flow Back: Large-Bore Aspiration Thrombectomy for Symptomatic Early Transjugular Intrahepatic Portosystemic Shunt (TIPS) Occlusion.
BibTeX
@article{angendohr2026study,
title = {{Study protocol of a prospective, non-interventional cohort study evaluating the benefits of transjugular intrahepatic portosystemic shunt in patients with hepatocellular carcinoma receiving first-line atezolizumab plus bevacizumab (NISTIPS TRITICC-4, IKF092)}},
author = {Carolin Angendohr and Christian Weigel and Anselm Kunstein and Markus Joerdens and Thorsten Goetze and Salah-Eddin Al-Batran and Bianca Zäpf and Maria Gonzalez-Carmona and Cennet Sahin and Marie-Luise Berres and Friedrich Foerster and Najib Ben Khaled and Christine Koch and Arne Kandulski and Henning Wege and Jonel Trebicka and Leonie S. Jochheim and Michael T. Dill and Christoph Springfeld and Severin Daum and Christoph Treese and Ursula Ehmer and Tom Luedde and Johannes Bode and Christoph Roderburg},
journal = {Future Oncology},
year = {2026},
month = oct,
doi = {10.1080/14796694.2026.2748246},
url = {https://doi.org/10.1080/14796694.2026.2748246},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Study protocol of a prospective, non-interventional cohort study evaluating the benefits of transjugular intrahepatic portosystemic shunt in patients with hepatocellular carcinoma receiving first-line atezolizumab plus bevacizumab (NISTIPS TRITICC-4, IKF092)
AU - Carolin Angendohr
AU - Christian Weigel
AU - Anselm Kunstein
AU - Markus Joerdens
AU - Thorsten Goetze
AU - Salah-Eddin Al-Batran
AU - Bianca Zäpf
AU - Maria Gonzalez-Carmona
AU - Cennet Sahin
AU - Marie-Luise Berres
AU - Friedrich Foerster
AU - Najib Ben Khaled
AU - Christine Koch
AU - Arne Kandulski
AU - Henning Wege
AU - Jonel Trebicka
AU - Leonie S. Jochheim
AU - Michael T. Dill
AU - Christoph Springfeld
AU - Severin Daum
AU - Christoph Treese
AU - Ursula Ehmer
AU - Tom Luedde
AU - Johannes Bode
AU - Christoph Roderburg
PY - 2026
DA - 2026/10/20
JO - Future Oncology
DO - 10.1080/14796694.2026.2748246
UR - https://doi.org/10.1080/14796694.2026.2748246
AB - Background: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality, with most patients diagnosed at an advanced stage. Atezolizumab plus bevacizumab is a current standard first-line therapy; however, outcomes are strongly influenced by underlying cirrhosis and clinically significant portal hypertension (CSPH). Complications such as ascites and variceal bleeding may limit treatment continuation, particularly as bevacizumab increases bleeding risk. Transjugular intrahepatic portosystemic shunt (TIPS) reduces portal pressure and may improve outcomes, but its role in patients receiving immunoncology-based systemic therapy remains unclear. Methods: NISTIPS TRITICC-4 is a prospective, multicentre, non-interventional cohort study conducted at up to 25 centers in Germany. A total of 350 adult patients with cirrhosis and unresectable or metastatic HCC receiving first-line atezolizumab plus bevacizumab will be enrolled. Patients are allocated to two cohorts: TIPS in situ plus atezolizumab and bevacizumab or atezolizumab plus bevacizumab alone, according to routine clinical practice. The primary endpoint is time to deterioration of liver function (TTDL), defined as persistent worsening of liver parameters for >4 weeks. Secondary endpoints include overall survival, time on treatment, overall response rate, time to new extrahepatic lesions or death, and safety with focus on bleeding and TIPS-related complications. Time-to-event endpoints will be analyzed using Kaplan–Meier methods and Cox models. Propensity score matching will be applied to adjust for confounding. Analyses are exploratory. Discussion: This study will provide real-world evidence on the impact of TIPS in HCC patients receiving atezolizumab plus bevacizumab and may support more individualized management strategies in this high-risk population. Clinical trial registration: www.clinicaltrials.gov identifier is NCT07365930
SN - 1479-6694
SN - 1744-8301
ER -